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Introduction & aims: Oral azithromycin maintenance therapy is frequently prescribed in CF as it has 
been shown to improve long-term clinical outcome. However, systemic azithromycin use is associated 
with toxic effects.  Entrapment of antimicrobial agents in liposomes has the potential to enable direct 
delivery to the site of infection in the lungs and to reduce toxic side-effects. Therefore, this study aimed 
to determine the antimicrobial activity of a novel liposomal azithromycin formulation against clinical 
respiratory isolates. 
 
Methods: Antimicrobial activity of free azithromycin and azithromycin loaded liposomes against clinical 
P. aeruginosa and S. aureus isolates was determined using minimum inhibitory concentration (MIC)/ 
minimum bactericidal concentration (MBC), time-kill and biofilm assays. Liposomal uptake by isolates 
was determined using flow cytometry analysis. 
 
Results: In general, there was no difference in MIC/MBC values for free and liposomal loaded 
azithromycin. The majority of P. aeruginosa and S. aureus isolates were resistant with MBCs ranging 
from 128 to >256 µg/ml and 8 to >256 µg/ml, respectively.  However, liposomal azithromycin was 
significantly more potent than free azithromycin in both prevention of P. aeruginosa biofilm formation 
and eradication of P. aeruginosa biofilms. Liposomal uptake ranged from 57 to 96 % for P. aeruginosa 
and from 58 to 78% for S. aureus.  
 
Conclusion: This novel liposomal azithromycin formulation could be potentially useful in the 
management of CF respiratory infection. 
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